SSG
GEVA

Summit Securities Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Summit Securities Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-10
Closed -$1K – 671
2013
Q2 		$1K Buy
+10
New +$456 ﹤0.01% 556

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Summit Securities Group's GEVA Position: Q1 2015 in Review

Summit Securities Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 100 shares — an estimated $9K sold.

Summit Securities Group first reported a position in GEVA in Q2 2013 and held it in 3 quarters. The position peaked at $21K in Q2 2013. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • Summit Securities Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Summit Securities Group sold 100 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $9K.
  • Summit Securities Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 3 quarters.
  • Summit Securities Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $21K in Q2 2013.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Summit Securities Group's 13F filing for Q1 2015, filed 22 Apr 2015.